Skip to main content
Public Health

Human papilloma virus (HPV)

For women in the EU aged 15-44, cervical cancer is the second most common form after breast cancer. Cervical cancer is caused by certain strains of human papilloma virus (HPV). In different studies, HPV was detected in more than 90% of cervical cancers.

There are vaccines that can prevent infection with the types of HPV that most commonly cause cancer. Countries with cervical cancer screening programs have substantially reduced cervical cancer incidence and deaths.

EU authorisation – three HPV vaccines

Following the green light from the scientific committee of the European Medicines Agency, the EU authorised the marketing of three HPV vaccines that prevent infections with the main strains of HPV that cause cervical cancer:

Vaccination

One of the goals of Europe’s Beating Cancer Plan is to eliminate cervical cancer by vaccinating young people against the Human papillomavirus (HPV) that causes it and is also linked to head and neck, and anal cancers.  

Specifically, the Plan calls for vaccinating at least 90% of the EU’s target population of girls and for significantly increasing the vaccination rate among boys.

In 2024, the Commission presented a proposal for a Council Recommendation on vaccine-preventable cancers to support EU countries in boosting the uptake of vaccination against Human Papillomaviruses (HPV) and Hepatitis B virus (HBV).

Recommendations to EU countries will include facilitating access to vaccination, targeted communication on the importance of HPV and HBV vaccination in a cancer prevention perspective and better monitoring of vaccination coverage rates to inform public health action.

Work on HPV by the ECDC

The European Centre for Disease Control (ECDC) provides information on HPV and cervical cancer.

Cancer screening

HPV vaccines do not give 100% protection against cervical cancer and vaccination is not a replacement for routine cervical screening. National authorities are encouraged to carry out organised population-wide cervical screening by smear test before introducing HPV vaccination.

This screening should take account of the European guidelines for quality assurance in cervical cancer screening and diagnosis.